Volume : 11, Issue : 10, October – 2024
Title:
AN COMPREHENSIVE OVERVIEW ON IN SILICO TRIALS
Authors :
Miss.Abburi Priyanka, Mrs.J.Bharathi, Dr.K.Venu Gopal
Abstract :
In silico studies are those that use computer software to create a virtual world within a computer .The task of finding novel drugs in the pharmaceutical industry is greatly aided by these drug design software programs .These designing tools and programs are used in molecular modelling ,gene sequencing and evaluating the three dimensional structure of molecules ,which can then be applied to the design and development of design .In addition to being a potent ,comprehensive ,and multidisciplinary system ,drug development and discovery is also an extremely difficult and time consuming process the primary focus of this book chapter was on various in silico methods types and their medicinal applications in various disorders it is demonstrated that in silico methods are computationally based techniques that use mathematical algorithms and computer simulations to examine the structure characteristics and activities of molecules .
In silico trials helps to minimize the errors such as data errors. It can predict the therapeutic potential of new drugs. This in silico techniques are mostly applied in the pharmaceutical production of invitro data to build models that facilitate the identification of new compounds by providing insight into their futures related to absorption, distribution, metabolism,and excretion .
Cite This Article:
Please cite this article in press Abburi Priyanka et al., An Comprehensive Overview On In Silico Trials.,Indo Am. J. P. Sci, 2024; 11 (10)
Number of Downloads : 10
References:
1.M.A. Mehmood, U. Sehar, N. Ahmad Use of bioinformatics tools in different spheres of life sciences J Data Min Genom Proteonomics, 5 (2) (2014), p. 1.
2. Badano A. In silico imaging: definition, possibilities and challenges. Nucl Inst Methods Phys Res Part A. 2011; 648:276–80.
3. Gong X, Glick SJ, Liu B, Vedula AA, Thacker S. A computer simulation study comparing lesion detection accuracy with digital mammography, breast tomosynthesis, and cone-beam CT breast imaging. Med Phys. 2006; 33(4):1041–52.
4. Badano A, Graff CG, Badal A, Sharma D, Zeng R, Samuelson FW, Glick SJ, Myers KJ. Evaluation of digital breast tomosynthesis as replacement of full-field digital mammography using an in-silico imaging trial. JAMA Netw Open. 2018; 1(7):185474.
5. B. Parvinian, et al. Credibility evidence for computational patient models used in the development of physiological closed-loop controlled devices for critical care medicine
6. R.M. Simon, D.O. Dixon, B. Freidlin A Bayesian model for evaluating specificity of treatment effects in clinical trials.
7. Bruynseels K., Santoni de Sio F., van den Hoven J. Digital Twins in Health Care: Ethical Implications of an Emerging Engineering Paradigm. Front. Genet. 2018;9:31. doi:
10.3389/fgene.2018.00031. [DOI] [PMC free article] [PubMed] [Google Scholar]. Informatics in Medicine Unlocked 28 (2022) 100862
[8] Haghighi O, et al. Homology modeling and molecular docking studies of glutamate dehydrogenase (GDH) from cyanobacterium Synechocystis sp. PCC 6803. Int J Pept Res Therapeut 2020;26(2):783–93.
[9] Haghighi O. In silico study of the structure and ligand preference of pyruvate kinases from cyanobacterium Synechocystis sp. PCC 6803. Appl Biochem Biotechnol 2021;193(11):3651–71.
[10] Bigdelou Z, et al. Investigation of specific binding of designed oligodeoxynucleotide decoys to transcription factors in HT29 cell line undergoing epithelial–mesenchymal transition (EMT). J Cell Physiol 2019;234(12): 22765–74.
[11] Rahmati M, et al. Suppressing the metastatic properties of the breast cancer cells using STAT3 decoy oligodeoxynucleotides: a promising approach for eradication
of cancer cells by differentiation therapy. J Cell Physiol 2020;235(6):5429–44.
[12] Behbahani M, Moradi M, Mohabatkar H. In silico design of a multi-epitope peptide construct as a potential vaccine candidate for Inuenza A based on neuraminidase protein. In silico Pharmacol 2021;9(1):1–13.
[13] Hufsky F, et al. Computational strategies to combat COVID-19: useful tools to accelerate SARS-CoV-2 and coronavirus research. Briengs Bioinf 2021;22(2): 642–63.
[14] Li Q, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med 2020;382(13):1199–207. https:// doi.org/10.1056/NEJMoa2001316.
[15] Dehelean CA, et al. SARS-CoV-2: repurposed drugs and novel therapeutic
approaches—insights into chemical structure—biological activity and toxicological screening. J Clin Med 2020;9(7):2084.
[16] Alimadadi A, et al. Articial Intelligence and Machine Learning to Fight COVID- 1952(4). MD: American Physiological Society Bethesda; 2020. p. 200–2. https:// doi.org/10.1152/physiolgenomics.00029.2020.
[17] Guedes IA, et al. Drug design and repurposing with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-synonym variants. Sci Rep 2021;11(1):5543.
[18] Alagumuthu M, Rajpoot S, Baig MS. Structure-based Design of novel peptidomimetics Targeting the SARS-CoV-2 spike protein. Cell Mol Bioeng 2020; 14(2):1–9.
[19] Zheng W, et al. Folding non-homologous proteins by coupling deep-learning contact maps with I-TASSER assembly simulations. Cell Rep Methods 2021: 100014.
[20] Kelley LA, et al. The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc 2015;10(6):845–58.
[21] Kong R, et al. COVID-19 Docking Server: a meta server for docking small molecules, peptides and antibodies against potential targets of COVID-19. Bioinformatics 2020;36(20):5109–11.
[22] Arantes PR, Saha A, Palermo G. Fighting covid-19 using molecular dynamics simulations. ACS Publications; 2020.
[23] Zoabi Y, Deri-Rozov S, Shomron N. Machine learning-based prediction of COVID- 19 diagnosis based on symptoms. NPJ Digit Med 2021;4(1):3.
[24] Lalmuanawma S, Hussain J, Chhakchhuak L. Applications of machine learning and articial intelligence for Covid-19 (SARS-CoV-2) pandemic: a review. Chaos, Solit. Fractals 2020; 139:110059.
[25] Dong S, et al. A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV). J Med Virol 2020;92(9):1542–8.
[26] Li Q, Peng W, Ou Y. Prediction and analysis of key protein structures of 2019- nCoV. Future Virol 2020;15(6):349–57.
[27] Baruah C, Devi P, Sharma DK. Sequence analysis and structure prediction of SARS-CoV-2 accessory proteins 9b and ORF14: evolutionary analysis indicates close relatedness to bat coronavirus. BioMed Res Int 2020; 2020:7234961.
[28] Vandelli A, et al. Structural analysis of SARS-CoV-2 genome and predictions of the human interactome. Nucleic Acids Res 2020;48(20):11270–83.
[29] Li T, et al. Phylogenetic supertree reveals detailed evolution of SARS-CoV-2. Sci Rep 2020;10(1):22366.
[30] Tabibzadeh A, et al. SARS-CoV-2 Molecular and Phylogenetic analysis in COVID.i